---
title: "Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280270239.md"
description: "Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise"
datetime: "2026-03-24T07:02:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280270239.md)
  - [en](https://longbridge.com/en/news/280270239.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280270239.md)
---

# Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise

Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LIXT.US](https://longbridge.com/en/quote/LIXT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [AMAM.US](https://longbridge.com/en/quote/AMAM.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [PLX.US](https://longbridge.com/en/quote/PLX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO](https://longbridge.com/en/news/287276384.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)